FormWeb • ondansetron

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search by class Show Therapeutic Classes

Add Formweb to your mobile device

Android iOS

Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

ondansetron

ondansetron

Formulary Serotonin Receptor Antagonists (5-HT3)Formulary

Drug Name	Form	Strength
Zuplenz	DISINTEGRATING STRIP, ORAL	4 mg, 8 mg
Zofran	SOLUTION, INJECTABLE	2 mg/mL
Zofran	SOLUTION, ORAL	4 mg/5 mL
Zofran ODT	TABLET, DISINTEGRATING, ORAL	4 mg, 8 mg
Zofran	TABLET, ORAL	4 mg, 8 mg

VIEW MORE 5-HT3 Receptor Antagonists

Comments:

ORDERED FORMULATION

FORMULARY INTERCHANGE

ondansetron (Zuplenz)

4 mg disintegrating strip oral
8 mg disintegrating strip oral

ondansetron (Zofran ODT)

4 mg disintegrating tablet oral
8 mg disintegrating tablet oral

Due to potential risk of QT interval prolongation, IV doses should not exceed 16 mg. HH P&T has approved limiting both parenteral and oral single doses to a maximum of 16 mg. Reviewed: January 27, 2015

Standardize piggyback solution to 50 mL NS

Reviewed: January 23, 2007, March 27, 2007 and September 23, 2008 (Ondansetron ODT) and December 14, 2010 (ZUPLENZ and January 22, 2013 (ondansetron ODT)

Last updated: Jun. 29, 2017

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.